AzTrials
AzTrials

Thyroid DysfunctionOHPLDONCT06272721

Hypothyroidism in Pregnancy and Neuropsychological Development in Children

A study testing Griffiths Scale in people with Thyroid Dysfunction and Pregnancy Related, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Thyroid dysfunction, particularly hypothyroidism and thyroid autoimmunity, impacts a significant proportion of pregnant women, affecting 3% and 17% respectively. The management of thyroid-stimulating hormone (TSH) levels is crucial, with subclinical hypothyroidism often defined by a TSH upper reference limit of 4… Read more about this study

Who is it for?
Ages 2 to 50 yearsHealthy volunteers can take part
What is being tested?
Griffiths Scale
Could I receive a placebo?
No, everyone receives an active treatment
How many people
104 participants
Where
1 siteItaly
Study dates
19 Feb 2024to 31 May 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 2 to 50 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult

Who may be able to join

  • Women aged above 18 and not beyond 50; Diagnosed with hypothyroidism during pregnancy; TSH values equal to or greater than 10 mU/L during pregnancy; Children aged between 2 and 6 years born to mothers with overt hypothyroidism during pregnancy; Signature of consent.
  • Women aged above 18 and not beyond 50; Absence of hypothyroidism during pregnancy; Children aged between 2 and 6 years born to mothers without overt hypothyroidism during pregnancy; Signature of consent.

Who cannot join

  • Presence of uncontrolled liver, kidney, diabetic, neurological, and psychiatric comorbidities prior to conception; Twin pregnancies; History of alcohol or smoking during pregnancy; History of infertility or assisted conception.
  • Presence of uncontrolled liver, kidney, diabetic, neurological, and psychiatric comorbidities prior to conception; Twin pregnancies; History of alcohol or smoking during pregnancy; History of infertility or assisted conception.

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • Fondazione Policlinico Universitario A. Gemelli IRCCS

    Roma, 00168

    ALFREDO PONTECORVI, +390630155701, alfredo.pontecorvi@policlinicogemelli.it

    ALFREDO PONTECORVI

Other trials in Italy

About this study

Official title: Investigation of the Association Between Hypothyroidism in Pregnancy and Neuropsychological Development in Children

Thyroid dysfunction, particularly hypothyroidism and thyroid autoimmunity, impacts a significant proportion of pregnant women, affecting 3% and 17% respectively. The management of thyroid-stimulating hormone (TSH) levels is crucial, with subclinical hypothyroidism often defined by a TSH upper reference limit of 4 mU/L, and overt hypothyroidism by TSH levels above 10 mU/L and potentially low free thyroxine (FT4) levels. Levothyroxine (LT4) treatment is strongly advised for TSH levels above 10 mU/L, with the timing of intervention being critical during the first trimester for optimal fetal brain development.

Research shows that untreated maternal hypothyroidism can significantly impact the neuropsychological development of the child, affecting cognitive, verbal, and motor skills. Even subclinical maternal hypothyroidism has been associated with lower IQ and motor scores in children. Early pregnancy intervention is key, as treatment after the first trimester may not improve children's neurocognitive outcomes.

Read more

Regarding sensory and linguistic development, evidence is mixed, but recent studies suggest that maternal hypothyroidism can lead to expressive language delays. The Development Quotient (DQ) is used to assess cognitive and motor development in children, with the Griffiths Mental Development Scales II being a common tool.

This study aims to explore the effects of treated maternal hypothyroidism during pregnancy on children's neurodevelopment, focusing on learning and language. It includes 31 women diagnosed with hypothyroidism and a control group of 21 euthyroid women, along with their children. The study emphasizes the importance of early detection and treatment of maternal hypothyroidism for preventing adverse neurodevelopmental outcomes in offspring. Statistical analysis will be conducted using SPSS, with a focus on maternal-fetal outcomes and cognitive-neuropsychological outcomes, highlighting the significance of early intervention.

Read the detailed description

Thyroid dysfunction is a not uncommon endocrine disorder during pregnancy, with hypothyroidism and thyroid autoimmunity affecting respectively 3% and 17% of expectant mothers. The value of thyroid-stimulating hormone (TSH) during pregnancy should be assessed in reference to a specific population and a trimester range, ideally defined by the reference laboratory or obtained from a similar population. When this is not possible, an upper reference limit of 4 mU/L (4 µIU/mL) may be used to define subclinical hypothyroidism. Elevated TSH values (above 10 mU/L (10 µIU/mL)) possibly associated with low levels of free thyroxine (FT4) define overt hypothyroidism. Current guidelines strongly recommend levothyroxine (LT4) therapy in women with TSH above 10 mU/L (10 µIU/mL), while recommendations regarding subclinical hypothyroidism are more debated and depend on antibody positivity. Regarding the timing of LT4 intervention, the most critical phase is the first trimester, as the fetal thyroid is fully functional after week 12, when thyroid organogenesis is complete. The consistent intake of thyroid hormones is crucial for brain maturation, influencing numerous aspects including migration, differentiation, and neural cell signaling. Data regarding the association between overt hypothyroidism and adverse pregnancy complications are quite solid. Gestational hypothyroidism has been linked to an increased risk of preterm birth, intrauterine growth restriction (IUGR) of fetuses, spontaneous abortion, and risk of fetal death, particularly when hypothyroidism was untreated or inadequately managed. Studies on the influence of maternal prenatal thyroid dysfunction show that it can alter cognitive, verbal, and motor abilities in children. Already in 1999, it was highlighted that children born to mothers with untreated hypothyroidism had a lower intelligence quotient (IQ). These negative effects have also been observed in subclinical hypothyroidism. Children of mothers with elevated TSH levels show reductions in intelligence and motor scores. Furthermore, lower intellectual development seems correlated with maternal TSH level, regardless of the presence of antibodies. Studies have also revealed that treatment of maternal hypothyroidism after the first trimester of pregnancy does not necessarily improve the neurocognitive abilities of children. This suggests that interventions are more effective if they occur in the early stages of pregnancy. Regarding sensory and linguistic development, the evidence is conflicting. Some studies have found no significant correlations, while others have observed that maternal hypothyroidism may be associated with delays in expressive language. A recent study showed a decrease in language scale scores in children born to mothers with overt hypothyroidism. This indicates that the balance of thyroid hormones during pregnancy is crucial for the optimal neurocognitive development of the child. The Development Quotient (DQ) is an index that measures cognitive and motor development in children, similar to the Intelligence Quotient (IQ), but specific for preschool and infant age. It includes tests that assess linguistic, motor, social, and problem-solving skills. A high score indicates normal or advanced development, while a low one may signal delays or the need for specific interventions. Among the tools to assess DQ, the Griffiths Mental Development Scales II are widely used for children from 0 to 6 years. These scales have six subscales that evaluate different functional areas, based on parent information and direct observations. The areas are: locomotion, personal-social interaction, learning and language, eye-hand coordination, performance, and practical reasoning (the latter not always assessed). The DQ is calculated by comparing the mental age with the chronological age of the child and is expressed as DQ. An average DQ stands at about 100 ± 15. The study will pay particular attention to specific neurocognitive areas such as learning and language. Furthermore, we will analyze the pregnancy outcome and complications in mothers. The aim of this study is to explore the connection between maternal hypothyroidism treated during pregnancy and the neurological development of the offspring, focusing on learning and language and examining related maternal obstetric complications. The study will include 31 women who were diagnosed with hypothyroidism and a control group of 21 euthyroid women. 31 children of hypothyroid women and 21 children of euthyroid women. The inclusion criteria encompass all women who were diagnosed with hypothyroidism - whether post-surgical or autoimmune, preexisting or newly diagnosed - presenting TSH values equal to or higher than 10 mU/L (10 µIU/mL) (n.v. 0.5-2.5) during pregnancy. The exclusion criteria applied to both groups involve the presence of uncontrolled liver, kidney, diabetic, neurological, and psychiatric comorbidities before conception, twin pregnancies, a history of alcohol consumption or smoking during pregnancy, and a history of infertility or assisted conception. The statistical analysis foresees that continuous data will be represented as mean ± standard deviation (SD), while categorical variables will be presented as frequency and percentage. In comparing baseline characteristics between groups, the Chi-square test will be used for categorical variables, while the independent Student's t-test will be applied for normally distributed continuous quantitative variables. The analysis of outcomes will be bifurcated into maternal-fetal outcomes and cognitive-neuropsychological outcomes. For comparisons between groups regarding outcomes, the Chi-square test will be used for categorical variables, the independent Student's t-test for normally distributed continuous quantitative variables, and the Mann-Whitney U test for non-normally distributed quantitative variables. A p-value of less than 0.05 will be considered statistically significant. Furthermore, a correlation analysis between two non-normally distributed quantitative variables will be conducted, where a p-value of less than 0.01 will be considered statistically significant. All statistical analyses will be performed using SPSS software (IBM) version 25

Being tested
Griffiths Scale

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Griffiths ScaleDiagnostic test

    The Griffiths Mental Development Scales II are key tools for assessing children's psychomotor development from ages 0 to 6, praised for their strong psychometric properties. They evaluate various functional areas through six subscales, combining parental reports and direct observations of the child's behavior. The areas include locomotion, personal-social interaction, learning and language, eye-hand coordination, and performance, excluding the optional practical reasoning section for older children in this study. The Development Quotient (DQ), calculated by comparing mental and chronological ages, indicates developmental progress or delay, with an average score around 100 ± 15.

Study groups in NCT06272721
Study groupRoleWhat they receive
Group 1: Children of women with overt hypothyroidism during pregnancyOther31 children undergoing neuropsychological testing for clinical practice, having their 31 mothers exhibited overt hypothyroidism during pregnancy.
Receives: Diagnostic Test: Griffiths Scale
Group 2: Children of women without overt hypothyroidism during pregnancyActive comparator21 children undergoing neuropsychological testing outside of clinical practice, as their 21 mothers did not exhibit overt hypothyroidism during pregnancy.
Receives: Diagnostic Test: Griffiths Scale

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. total development quotient measured using the Griffiths scale

    Difference in the total Development Quotient (DQ) measured using the Griffiths scale, which evaluates different areas of neurodevelopment, between children born to mothers with overt hypothyroidism (TSH > 10 mIU/L) and children born to women without overt hypothyroidism.

    Difference in the total Development Quotient (DQ) measured using the Griffiths scale, which evaluates different areas of neurodevelopment, between children born to mothers with overt hypothyroidism (TSH > 10 mIU/L) and children born to women without overt hypothyroidism.

    Measured: 30 minuts

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Feb 2024
  2. Study start19 Feb 2024 (estimated)
  3. Primary completion30 Apr 2024 (estimated)
  4. Study completion31 May 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
104 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06272721
Sponsor's protocol ID
6272
Acronym
OHPLDO
Status last verified
Feb 2024
First submitted
15 Feb 2024
Last updated
22 Feb 2024
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Griffiths Scale in people with Thyroid Dysfunction and Pregnancy Related, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 22 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

total development quotient measured using the Griffiths scale (time frame: 30 minuts). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Feb 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in